Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT – Get Free Report) saw a large drop in short interest in October. As of October 15th, there was short interest totaling 67,594 shares, a drop of 41.3% from the September 30th total of 115,090 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 3,118,131 shares, the short-interest ratio is presently 0.0 days.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (d)” rating on shares of Zhengye Biotechnology in a research note on Friday, October 16th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has a consensus rating of “Sell”.
Get Our Latest Analysis on Zhengye Biotechnology
Zhengye Biotechnology Trading Down 9.1%
NASDAQ:ZYBT traded down $0.13 during trading hours on Friday, reaching $1.30. 122,913 shares of the stock were exchanged, compared to its average volume of 1,753,646. The firm has a 50 day simple moving average of $1.48 and a 200-day simple moving average of $1.16. Zhengye Biotechnology has a 52 week low of $0.62 and a 52 week high of $8.01.
About Zhengye Biotechnology
Zhengye Biotechnology Group Co, Ltd. is a China-based biotechnology company focused on developing, manufacturing and selling biological products for the agricultural and animal husbandry industries. Its business is centered on applying microbial technologies to support animal health, livestock production and crop cultivation.
The company’s product offerings include microbial-based products used in animal feed and agricultural production, as well as related biological solutions intended to improve farming efficiency and promote healthier livestock and crops.
Featured Stories
- Five stocks we like better than Zhengye Biotechnology
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Zhengye Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhengye Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
